CRi, 3DHISTECH align on digital pathology

Manjula Puthenedam, PhD, | | Health Imaging | Molecular Imaging
Cambridge Research & Instrumentation (CRi) has agreed to distribute 3DHISTECH’s suite of digital slide scanners and software applications in North America, develope and distribute a next generation of product offerings.

George Abe, president and CEO of the Woburn, Mass.-based CRi, said that digital pathology technologies were providing important infrastructure for emerging molecular diagnostic approaches based on disease-related biomarkers.

3DHISTECH, based in Budapest, Hungary, offers a broad line of digital pathology products, scanners and software for slide viewing, quantitation, telemedicine, and image management, said CRi.

Manjula Puthenedam, PhD,

Related Content

PET method offers new insight into inflammation of the brain
New PET imaging method could improve our understanding of long COVID
FDA approves new prostate cancer imaging agent with extended shelf life
New PET study offers insight into how dopamine drives executive function
New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.